HS
RIGL icon

HighVista Strategies’s Rigel Pharmaceuticals RIGL Stock Holding History

HighVista Strategies’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-2,174
Closed -$79K – 105
2021
Q3 		$79K Buy
2,174
+851
+64% +$33.5K 0.05% 118
2021
Q2 		$57K Hold
1,323
– – 0.04% 115
2021
Q1 		$45K Sell
1,323
-931
-41% -$36.9K 0.03% 125
2020
Q4 		$79K Sell
2,254
-926
-29% -$26.8K 0.05% 103
2020
Q3 		$76K Sell
3,180
-840
-21% -$20.6K 0.06% 98
2020
Q2 		$74K Buy
4,020
+1,450
+56% +$26.1K 0.06% 83
2020
Q1 		$40K Sell
2,570
-810
-24% -$17.2K 0.04% 54
2019
Q4 		$72K Hold
3,380
– – 0.05% 102
2019
Q3 		$63K Buy
+3,380
New +$69.8K 0.04% 104

Other funds holding RIGL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
TA
Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return

HighVista Strategies's RIGL Position: Q4 2021 in Review

HighVista Strategies sold out of Rigel Pharmaceuticals (RIGL) in Q4 2021, closing a stake of 2,174 shares — an estimated $79K sold.

HighVista Strategies first reported a position in RIGL in Q3 2019 and held it in 9 quarters. The position peaked at $79K in Q3 2021. 162 funds tracked by Wall St. Rank hold RIGL as of Q4 2021.

  • HighVista Strategies reported no remaining Rigel Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • HighVista Strategies sold 2,174 Rigel Pharmaceuticals shares in Q4 2021, an estimated $79K.
  • HighVista Strategies first reported a position in Rigel Pharmaceuticals in Q3 2019 and held it in 9 quarters.
  • HighVista Strategies's Rigel Pharmaceuticals position peaked at $79K in Q3 2021.
  • 162 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q4 2021.

Based on HighVista Strategies's 13F filing for Q4 2021, filed 14 Feb 2022.